Autosomal dominant hereditary spastic paraplegia (AD-HSP) is a genetically heterogeneous
Introduction
Spastic paraplegias are a genetically heterogeneous group of diseases that share a defect of the axons of the pyramidal tracts. Both, corticospinal tracts and dorsal column fibres are affected by degeneration. The universal clinical sign of the disease is progressive weakness and spasticity of the lower limbs. 1 Among the hereditary spastic paraplegias (HSP), pure and complicated forms have been described and autosomal recessive, autosomal dominant and X-linked patterns of inheritance reported.
Immunofluorescence analysis showed that paraplegin localises to mitochondria and muscle biopsies from patients with paraplegin mutations showed mitochondrial OXPHOS defects, thus suggesting a mechanism for neurodegeneration.
The first gene that is mutated in AD-HSP patients, SPG4, was identified very recently. 16 Its open reading frame encodes a protein, spastin, of 616 amino acids. The C-terminus shows high homology to AAA proteins. The AAA cassette 17 is localised between amino acids 342 and 599 in the spastin sequence. The three conserved ATPase domains, including Walker motifs A and B 18 and the AAA minimal consensus, were located in the AAA cassette between amino acid positions 382-389, 437-442 and 480-498, respectively. Walker motif A, also called p-loop, which corresponds to the ATP-binding domain, and Walker motif B are highly conserved between spastin and all AAA family members. The AAA protein family is a group of ATPases with diverse functions. Spastin is probably involved in the assembly or function of nuclear protein complexes. 16 We have analysed the SPG4 gene in five German AD-HSP families and one HSP patient without family history to investigate whether this gene might also be affected in patients other than the original sample. Additionally, we have addressed the frequency and type of SPG4 variants and their predicted functional consequences for the peptide with respect to the clinical phenotype. Here we present four novel mutations in the SPG4 gene, one missense, one frame-shift and two splice mutations that were both shown to cause exon skipping.
Materials and methods

Patients
We analysed six independent index cases with spastic paraplegia. All of them are of German origin. Patient 1 is from the original family in whom we previously reported linkage to the SPG4 locus and evidence for anticipation. 8 All patients
were seen and investigated clinically by experienced neurologists. The age of onset varied widely from 1 to 55 years. None of the patients had a complicated form of HSP. Two obligate carriers from families 1 and 3 considered themselves unaffected, despite presenting mild signs on neurological investigation. Five of six patients showed autosomal dominant inheritance of the disorder. The sixth case is a singleton, but it is not known whether the father was affected. After informed consent was obtained, high molecular weight genomic DNA was prepared from peripheral blood leukocytes of AD-HSP patients and normal controls by standard methods.
Linkage analysis
Microsatellite genotypes were determined at the AD-HSP loci SPG3, SPG4 and SPG6. In larger families, two-point linkage data were calculated with the LINKAGE program package, version 5.10.
PCR
The genomic DNA sequence of the human SPG4 gene has been determined, 16 permitting the design of PCR primers from intronic sequences. PCR and sequencing primers were those used in the previous study 16 (http://www.genoscope.cns.fr) except for sequencing primers spa2c (TAGTG-TACTCTTCATACGATCT), spa5c (GTTTTACAAATGTTT-GCTTGTC), spa10m (AGATAGTCTTTAAGCTTGCCC) and spa16c (CCTTCAACAATTTCAACTGC). PCR was performed with 20 ng of DNA, 10 mM Tris, 50 mM KCl, 1.5 mM MgCl 2 , 100 µM of each dNTP, 1 µM of each primer and 0.5 u Taq polymerase (PE Applied Biosystems, Weiterstadt, Germany) in a volume of 30 µl. PCR was carried out in GeneAmp 9600 thermo cyclers (PE Applied Biosystems), starting with an initial denaturation of 5 min at 94°C followed by 3 cycles at decreasing annealing temperatures. 30 cycles were run for 20 s at 94°C, 20 s at a primer-specific annealing temperature and 40 s at 72°C followed by a final elongation of 5 min at 72°C.
Sequencing
PCR products were purified with Qiaquick PCR purification kit (Qiagen, Hilden, Germany). PCR fragments were sequenced directly or after cloning (TA Cloning Kit, Invitrogen, Groningen, The Netherlands) using Big-Dye-Terminator Cycle Sequencing Kit (PE Applied Biosystems). Sequencing reactions were purified with Dye-ex Spin kit (Qiagen) and run and analysed on an ABI Prism 310 Genetic Analyzer (PE Applied Biosystems).
Restriction enzyme analysis
Mutations D441G and 1853 + 1G→T were analysed by HphI and MnlI restriction enzymes (New England Biolabs, Frankfurt, Germany) respectively. PCR products spa11a/spa12m and spa16c/spa16m were digested according to the manufacturer's conditions and separated on 2% agarose gels.
RT-PCR
In families with mutations that could affect splicing, total RNA from blood lymphocytes was extracted from affected individuals and controls using Trizol (Life Technologies, Karlsruhe, Germany). cDNA synthesis was performed by incubating approximately 1 µg RNA, 100 pmol random hexamer primers (Pharmacia, Freiburg, Germany) and 200 u Superscript II (Life Technologies) according to standard procedures. Since the mutations under investigation potentially affected exons 11, 12 and 16, we carried out a PCR which generated a fragment from exon 10 to 17, using primers spaC10 (TGGGAGAAGGAGAGAAATTG) and spaC17 (CAAGGATTCAGTGAAGTCAG). PCR was performed with0.5 u Taq polymerase (PE Applied Biosystems) in a volume of 50 µl in a GeneAmp 9600 thermocycler (PE Applied Biosystems), starting with an initial denaturation of 5 min at 94°C followed by 4 cycles at annealing temperatures, reducing from 63°C to 57°C. Thereafter 30 cycles were run for 15 s at 93°C, 15 s at 55°C and 45 s at 72°C. The final elongation at 72°C was 5 min. PCR products were separated on 2% agarose gels in 1 ϫ TAE buffer. Individual bands were visualised on a long-wavelength UV transilluminator and excised by using sterile scalpels. Gel slices were centrifuged through Ultrafree-DA columns (Millipore, Eschborn, Germany) and diluted in 500 µl H 2 O. 1 µl was then re-amplified and sequenced as described above.
Results
Initially, we investigated all families for linkage to the SPG4 locus. Within the five families, affected persons shared a common microsatellite marker haplotype but only family 1 gave a significant lod score (4.02 at Θ = 0.00). Subsequently, we investigated these five unrelated families with AD-HSP and one singleton patient with spastic paraplegia for mutations in the SPG4 gene. We identified four different mutations that have not been described before (Table 1) .
In family 1, direct sequencing of the PCR product corresponding to exon 11 revealed heterozygosity for an A to G substitution of the first nucleotide of this exon. This alteration causes an aspartic acid to glycine exchange (D441G) in the Walker B motif of the peptide. Within this motif of six amino acids (IIFIDE), the fifth position is D (aspartic acid) in eight of eight proteins that exhibit high homology to spastin. 16 Aspartic acid is very polar and thus nearly always found on the outside of proteins, whereas glycine is non-polar and tends to be on the inside. Consequently, strong effects of aspartic acid to glycine mutations are also described in several other genes, eg in the fibrillin 1 gene, where it causes a severe form of Marfan syndrome. 19 Moreover, D441G creates a new restriction enzyme site for HphI. Therefore, we confirmed the mutation in the index patient by HphI digestion of the PCR product and also showed co-segregation of the mutation with the phenotype in this family (Figure 1 ). Since mutations of the first or last nucleotide in the exon were suggested to affect splicing, 20 we extracted lymphocyte RNA and performed an RT-PCR that spans exons 10-17. However, we only obtained the 521 bp band expected, but no aberrant bands. In family 3, direct sequencing of exon 16 PCR product showed heterozygosity for a G to T mutation in the donor splice site in intron 16, 1853 + 1g→t. Since this mutation destroys an MnlI site, digestion of exon 16 PCR product with MnlI was used to confirm the co-segregation of mutation and disorder. To investigate the effect of 1853 + 1g→t on SPG4 splicing, we amplified an RT-PCR product that spans exons 10 to 17 from lymphocyte RNA. In addition to the expected band another smaller and very weak band was seen on agarose gels (Figure 2 ). After excision from the gel and re-amplification, the aberrant band was sequenced from both directions, thereby demonstrating skipping of exon 16 (Figure 3) . This observation is in accordance with expectations since mutations in the donor splice site predominantly cause skipping of the adjacent exon. 21 The 1853 + 1g→t mRNA bears a frame shift and a premature termination signal at codon 570. If translated, a spastin with erroneous amino acids at codons 563-569 would result. The functionally important structures, the Walker A and B motifs and the AAA minimal consensus sequence, would not be affected by this mutation. However, our RT-PCR data show that the dose of the mutant mRNA is drastically reduced. We estimate the ratio of normal to mutant mRNA at approximately 100 to 1. In family 4, direct sequencing of the PCR product corresponding to exon 12 revealed heterozygosity for an AGgt deletion that affects two nucleotides of exon 12 and two nucleotides of the donor splice site in intron 12. To analyse the effect of this 1617-1618 + 2del mutation on SPG4 splicing, we performed an RT-PCR that spans exons 10-17. In addition to the 521 bp band of the wild type allele, we obtained smaller and very weak bands (Figure 2 ). These were excised from the gel, re-amplified and sequenced from both directions. We identified two aberrantly spliced mRNAs, one showing skipping of exons 11 and 12 and the other one missing exons 11, 12 and 13 ( Figure 4 ). Mutations at splice sites often lead to the observation of multiple cDNA species after RT-PCR analysis. Sometimes mRNAs with multiple skipped exons are generated from the mutant DNA. In addition, splice mutations may exert a pleiotropic effect in that they lead to the generation of several differently spliced mRNAs. For example, a splice donor mutation in intron 5 of the HPRT gene led to (i) inclusion of intron 5, (ii) exclusion of exons 4 and 5 and (iii) exclusion of exons 2-6. 22 The 1617-1618 + 2del mRNAs without exons 11-12 and without exons 11-13 show frame shifts and premature termination signals at codons 472 and 447 respectively. If translated, spastin proteins with erroneous amino acids at codons 441-471 and 441-446 would result from this deletion. In both cases, the Walker B motif and the AAA minimal consensus sequence would not be present in such spastin. But, like the 1853 + 1g→t mutation, the doses of mutant mRNAs are reduced by a factor of approximately 100, which suggests that mutant SPG4 mRNAs are highly unstable. In family 6, direct sequencing of exon 9 PCR product revealed heterozygosity for a TATAA deletion in exon 9, Spastic paraplegia caused by SPG4 mutations y 1340-1344del. This mutation causes a frame shift in the SPG4 open reading frame from codon 405 to 440, where a premature termination codon is created. Such spastin protein would lack two of its functional domains, the Walker motif B and the AAA minimal consensus sequence.
The mutations D441G, 1340-1344del, 1617-1618 + 2del and 1853 + 1g→t were not found on 180 chromosomes of normal individuals of German origin.
In family 2 and in singleton patient 5, we did not find mutations in SPG4 exons 1-17, the flanking intronic sequences and 200 bp of the 5' untranslated region.
Discussion
Mutations on chromosome 2p21-p22 cause approximately 40-50% of AD-HSP. The mutant gene at this locus, SPG4, was recently identified by positional cloning. 16 Here, we describe four novel SPG4 mutations, thus confirming that they are relatively frequently found in AD-HSP patients.
No mutations were found in a patient without a family history and in a family where two definitely affected persons showed an identical haplotype, which was also present in a 23-year-old, so far unaffected person. We cannot exclude that large chromosomal re-arrangements might have occurred in the SPG4 gene in family 2 and patient 5. For example, the deletion of complete exons, including the adjacent intronic sequences, cannot be found by the approach we have used. These large deletions could be identified by Southern blotting, which is therefore a conceivable method for the further analysis of AD-HSP patients without 'small' SPG4 mutations. Alternatively, mutations at other AD-HSP loci need to be considered.
SPG4 mutations and their functional consequences
The SPG4 mutation D441G destroys one of the most conserved sites of the protein, the Walker motif B of the AAA cassette. The mutation 1340-1344del causes a spastin protein that would lack two of its three highly conserved functional domains, the Walker motif B and the AAA minimal consensus sequence. The SPG4 splice mutations 1853 + 1g→t and 1617-1618 + 2del lead to exon skipping and drastically reduced doses of mutant mRNAs which suggests that they are highly unstable. Consequently, mutant spastin would be expressed, if at all, at extremely low levels and hence could not have a dominant negative effect (gain of function). Instead of this, our data support a haploinsufficiency mechanism as previously reported 16 where spastin dosage would be a very critical factor for axon maintenance.
Genotype/phenotype correlation
The intra-familial variability of severity and age of onset of the disease indicates that there cannot be a tight genotype/ phenotype correlation. We predicted severe functional disadvantages for all the four novel mutations described here, since they destroy highly conserved functional domains. AD-HSP families. We had clinically observed a striking decrease in the age of onset in family 1 of 10.8 years on average per transmitting meiosis. 8 However, looking for expanded trinucleotide repeats by the repeat expansion detection method, 25 we found that anticipation was not associated with expansion of repeats (Hatchwell and Bürger, unpublished). We show here, that this family anticipates a missense mutation in the SPG4 gene, D441G. Therefore we conclude that the clinically observed anticipation is due to an ascertainment bias. This was also demonstrated by clinical studies. 26, 27 In conclusion, we present here four novel mutations in the SPG4 gene, one missense, one frame shift and two splice mutations. All mutations are predicted to cause loss of functional protein. Our data suggest that SPG4 mutations exert their dominant effect not by gain of function, but by loss of spastin dosage. We hypothesise that a threshold level of spastin is critical for axonal preservation. This would explain the variable expressivity and incomplete penetrance of SPG4-linked AD-HSP. Moreover, increasing the expression of spastin might be a therapeutic option in the future. However, further studies on mutant spastin in AD-HSP patients as well as in an animal model are necessary to support our hypotheses.
